Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| endothelial cell | 8 studies | 28% ± 7% | |
| adipocyte | 5 studies | 22% ± 9% | |
| GABAergic neuron | 3 studies | 25% ± 3% | |
| glutamatergic neuron | 3 studies | 35% ± 7% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 3 studies | 26% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 96% | 120.42 | 1384 / 1445 | 92% | 12.93 | 169 / 183 |
| bladder | 100% | 1714.29 | 21 / 21 | 88% | 37.14 | 441 / 504 |
| stomach | 100% | 550.37 | 358 / 359 | 87% | 12.34 | 250 / 286 |
| prostate | 100% | 204.04 | 244 / 245 | 87% | 10.01 | 436 / 502 |
| breast | 100% | 583.93 | 458 / 459 | 84% | 9.23 | 935 / 1118 |
| intestine | 96% | 135.79 | 926 / 966 | 85% | 6.88 | 446 / 527 |
| pancreas | 99% | 230.16 | 324 / 328 | 81% | 11.21 | 145 / 178 |
| thymus | 99% | 168.58 | 649 / 653 | 75% | 5.75 | 452 / 605 |
| lung | 90% | 109.32 | 518 / 578 | 82% | 6.33 | 946 / 1155 |
| ovary | 93% | 91.89 | 168 / 180 | 75% | 5.26 | 322 / 430 |
| uterus | 98% | 131.64 | 167 / 170 | 60% | 6.48 | 277 / 459 |
| kidney | 91% | 133.11 | 81 / 89 | 65% | 5.12 | 586 / 901 |
| adrenal gland | 98% | 140.30 | 252 / 258 | 35% | 1.18 | 81 / 230 |
| skin | 90% | 200.96 | 1634 / 1809 | 37% | 1.22 | 175 / 472 |
| brain | 84% | 117.65 | 2227 / 2642 | 41% | 1.30 | 289 / 705 |
| adipose | 100% | 762.71 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 100% | 7.89 | 1 / 1 |
| blood vessel | 97% | 165.79 | 1301 / 1335 | 0% | 0 | 0 / 0 |
| heart | 97% | 195.40 | 836 / 861 | 0% | 0 | 0 / 0 |
| spleen | 91% | 85.71 | 220 / 241 | 0% | 0 | 0 / 0 |
| muscle | 83% | 74.90 | 666 / 803 | 0% | 0 | 0 / 0 |
| liver | 66% | 70.31 | 150 / 226 | 14% | 0.51 | 58 / 406 |
| tonsil | 0% | 0 | 0 / 0 | 69% | 5.23 | 31 / 45 |
| lymph node | 0% | 0 | 0 / 0 | 31% | 0.97 | 9 / 29 |
| peripheral blood | 20% | 51.26 | 184 / 929 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 4% | 0.10 | 3 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0060049 | Biological process | regulation of protein glycosylation |
| GO_0006919 | Biological process | activation of cysteine-type endopeptidase activity involved in apoptotic process |
| GO_0071466 | Biological process | cellular response to xenobiotic stimulus |
| GO_0006974 | Biological process | DNA damage response |
| GO_0001953 | Biological process | negative regulation of cell-matrix adhesion |
| GO_0033629 | Biological process | negative regulation of cell adhesion mediated by integrin |
| GO_0046514 | Biological process | ceramide catabolic process |
| GO_0030149 | Biological process | sphingolipid catabolic process |
| GO_0042981 | Biological process | regulation of apoptotic process |
| GO_0010506 | Biological process | regulation of autophagy |
| GO_0046512 | Biological process | sphingosine biosynthetic process |
| GO_0032526 | Biological process | response to retinoic acid |
| GO_0008284 | Biological process | positive regulation of cell population proliferation |
| GO_0030330 | Biological process | DNA damage response, signal transduction by p53 class mediator |
| GO_0005794 | Cellular component | Golgi apparatus |
| GO_0000139 | Cellular component | Golgi membrane |
| GO_0017040 | Molecular function | N-acylsphingosine amidohydrolase activity |
| GO_0102121 | Molecular function | ceramidase activity |
| GO_0046872 | Molecular function | metal ion binding |
| GO_0071633 | Molecular function | dihydroceramidase activity |
| Gene name | ACER2 |
| Protein name | Alkaline ceramidase 2 (AlkCDase 2) (Alkaline CDase 2) (haCER2) (EC 3.5.1.-) (EC 3.5.1.23) (Acylsphingosine deacylase 3-like) (N-acylsphingosine amidohydrolase 3-like) |
| Synonyms | PP11646 ASAH3L |
| Description | FUNCTION: Golgi ceramidase that catalyzes the hydrolysis of ceramides into sphingoid bases like sphingosine and free fatty acids at alkaline pH . Ceramides, sphingosine, and its phosphorylated form sphingosine-1-phosphate are bioactive lipids that mediate cellular signaling pathways regulating several biological processes including cell proliferation, apoptosis and differentiation . Has a better catalytic efficiency towards unsaturated long-chain ceramides, including C18:1-, C20:1- and C24:1-ceramides . Saturated long-chain ceramides and unsaturated very long-chain ceramides are also good substrates, whereas saturated very long-chain ceramides and short-chain ceramides are poor substrates . Also hydrolyzes dihydroceramides to produce dihydrosphingosine . It is the ceramidase that controls the levels of circulating sphingosine-1-phosphate and dihydrosphingosine-1-phosphate in plasma through their production by hematopoietic cells (By similarity). Regulates cell proliferation, autophagy and apoptosis by the production of sphingosine and sphingosine-1-phosphate . As part of a p53/TP53-dependent pathway, promotes for instance autophagy and apoptosis in response to DNA damage . Through the production of sphingosine, may also regulate the function of the Golgi complex and regulate the glycosylation of proteins . . |
| Accessions | Q5QJU3 ENST00000340967.3 [Q5QJU3-1] |